CD274 and plasma cell myeloma: Combination of PD-1/PDL-1 monoclonal antibodies with other active myeloma drugs including carfilzomib (proteasome inhibitor), daratumumab (anti CD38 mab) and elotuzumab (anti SLAMF7 mab) are also being tested.